In vitro biotransformation of surfactants in fish. Part I: linear alkylbenzene sulfonate (C12-LAS) and alcohol ethoxylate (C13EO8).
Developing regulatory activities (e.g., REACh, [DGEE. 2003. Directorates General Enterprise and Environment. The new EU chemicals legislation REACH. DG Enterprise, Brussels, Belgium. (http://www.europa.eu.int/comm/enterprise/reach/index_en.htm)]) will require bioaccumulation to be assessed for thousands of chemicals. Further, there is increasing pressure to reduce, refine or replace animal tests. Given this scenario, there is an urgent need to evaluate the feasibility of in vitro systems to supply data useful for bioaccumulation estimation. Subcellular and cellular hepatic systems were tested to determine the biotransformation of two surfactants: C12-2-LAS (2-phenyl dodecane p-sulfonate) and an alcohol ethoxylate C13EO8 (Octaethylene glycol monotridecyl ether). The subcellular systems tested were liver homogenates and microsomes from the common carp (Cyprinus carpio) and rainbow trout (Oncorhynchus mykiss). Cellular systems consisted of primary hepatocytes from the common carp (Cyprinus carpio) and PLHC-1 cells, hepatocarcinoma cells from the desert topminnow (Poeciliopsis lucida). All in vitro systems were exposed to radiolabeled test compounds and assayed for biotransformation using liquid scintillation and thin layer chromatographic methods. First-order kinetics were used to estimate rates of biotransformation. Bioconcentration of test materials in fish were predicted using an in vitro to in vivo metabolic rate extrapolation model linked to a mass-balance model commonly used to predict bioaccumulation in fish. Subcellular biotransformation rates for each of the surfactants were greatest with microsomes. Cellular loss rates exceeded subcellular rates, leading to lower predicted BCF values. Predicted BCFs corresponded closely to measured values in several fish species, verifying the utility of in vitro systems in refining Kow-only-based BCFs via the inclusion of biotransformation rates.
Dyer
Scott D
SD
The Procter and Gamble Company, Central Product Safety Division, Miami Valley Innovation Center, Cincinnati, OH 45253, USA. dyer.sd@pg.com
Bernhard
Mary Jo
MJ
Cowan-Ellsberry
Christina
C
Perdu-Durand
Elisabeth
E
Demmerle
Susanne
S
Cravedi
Jean-Pierre
JP
D000438:Alcohols / Q000493:pharmacokinetics*; D017738:Alkanesulfonic Acids / Q000493:pharmacokinetics*; D000818:Animals; D001711:Biotransformation; D002347:Carps / Q000378:metabolism*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002855:Chromatography, Thin Layer; D022781:Hepatocytes / Q000378:metabolism; D007700:Kinetics; D008862:Microsomes, Liver / Q000378:metabolism; D017686:Oncorhynchus mykiss / Q000378:metabolism*; D013347:Subcellular Fractions / Q000378:metabolism; D013501:Surface-Active Agents / Q000493:pharmacokinetics*
D000438:Alcohols; D017738:Alkanesulfonic Acids; D013501:Surface-Active Agents; C030641:alkylbenzyl sulfonic acid; C061143:Neodol-12